On September 25, 2024, Keith Manchester, Director at Roivant Sciences Ltd (ROIV, Financial), executed a sale of 503,000 shares of the company, according to the SEC Filing. Following this transaction, the insider now owns 1,277,178 shares of the company.
Roivant Sciences Ltd focuses on applying technology to drug development and aims to rapidly develop innovative medicines through a novel form of industrial organization in research and development. The company's approach is to streamline the process of bringing promising drug candidates to market.
Over the past year, Keith Manchester has sold a total of 7,399,144 shares and has not purchased any shares. This recent transaction continues a trend of insider sales at Roivant Sciences Ltd, with a total of 12 insider sales and no insider buys reported over the last year.
Shares of Roivant Sciences Ltd were trading at $11.66 on the day of the transaction. The company has a market cap of approximately $8.56 billion. The price-earnings ratio of Roivant Sciences Ltd stands at 2.08, significantly lower than the industry median of 25.52 and below the company’s historical median.
The stock's valuation according to GF Value is $16.48, suggesting that with a current price of $11.66, Roivant Sciences Ltd is potentially undervalued with a price-to-GF-Value ratio of 0.71. This valuation indicates a "Possible Value Trap, Think Twice" status based on its GF Value.
The GF Value is calculated considering historical trading multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company’s past returns and growth, and future business performance estimates from Morningstar analysts.
This insider sale might be of interest to investors tracking insider behaviors and evaluating the stock's current valuation metrics and market performance.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
